OS Therapies (NYSEAMERICAN:OSTX) Given “Buy” Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of OS Therapies (NYSEAMERICAN:OSTX) in a report released on Thursday morning,Benzinga reports. D. Boral Capital currently has a $20.00 price objective on the stock.

Other analysts have also issued research reports about the company. Zacks Research upgraded OS Therapies from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Lake Street Capital cut their price objective on shares of OS Therapies from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $18.50.

OS Therapies Trading Down 4.5%

Shares of NYSEAMERICAN OSTX opened at $1.27 on Thursday. OS Therapies has a 12-month low of $1.12 and a 12-month high of $2.98. The firm’s 50-day moving average price is $1.56 and its 200-day moving average price is $1.83. The stock has a market capitalization of $44.72 million, a price-to-earnings ratio of -1.55 and a beta of -3.79.

OS Therapies (NYSEAMERICAN:OSTX) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter. On average, equities analysts predict that OS Therapies will post -0.64 EPS for the current fiscal year.

Institutional Trading of OS Therapies

Institutional investors and hedge funds have recently made changes to their positions in the business. Susquehanna International Group LLP purchased a new stake in shares of OS Therapies during the third quarter valued at $29,000. Mercer Global Advisors Inc. ADV purchased a new position in OS Therapies in the 3rd quarter worth about $40,000. Ground Swell Capital LLC bought a new stake in OS Therapies during the 3rd quarter valued at about $40,000. Bridgeway Capital Management LLC purchased a new stake in OS Therapies in the 2nd quarter valued at about $47,000. Finally, XTX Topco Ltd bought a new position in OS Therapies in the 2nd quarter worth about $63,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.